Pharmagreen Biotech Inc. (PHBI) Announces Exciting Revenue Potential for Its Project
Pharmagreen Biotech (OTC PINKS: PHBI) has announced significant revenue potential from its new project focused on producing Live Rosin, a high-quality cannabis concentrate. CEO Peter Wojcik detailed the company's proprietary extraction technique and Standard Organic Non-Spray Cultivation Procedures, which aim to produce 6,000 liters of Live Rosin per 100-acre farm per crop cycle. With 4-5 crop cycles per year, Pharmagreen projects revenues ranging from $19 million to $381 million in year 1, and $32 million to $635 million by year 3, depending on the price per gram. The company is seeking distributors and partnerships, and exploring the acquisition of a cGMP-certified cannabis lab in Europe. However, these projections depend on securing necessary licenses, permits, land leases, funding, and market access.
Pharmagreen Biotech (OTC PINKS: PHBI) ha annunciato un significativo potenziale di guadagno dal suo nuovo progetto incentrato sulla produzione di Live Rosin, un concentrato di cannabis di alta qualità. Il CEO Peter Wojcik ha descritto la tecnica di estrazione proprietaria dell'azienda e le Procedure di Coltivazione Organica Standard Non-Verniciate, che mirano a produrre 6.000 litri di Live Rosin per ogni fattoria di 100 acri per ciclo di coltivazione. Con 4-5 cicli di coltivazione all'anno, Pharmagreen prevede ricavi compresi tra 19 milioni e 381 milioni di dollari nel primo anno, e tra 32 milioni e 635 milioni di dollari entro il terzo anno, a seconda del prezzo al grammo. L'azienda sta cercando distributori e partnership, ed esplorando l'acquisizione di un laboratorio cannabis certificato cGMP in Europa. Tuttavia, queste proiezioni dipendono dal conseguimento delle licenze necessarie, dei permessi, dei contratti di affitto del terreno, dei finanziamenti e dell'accesso al mercato.
Pharmagreen Biotech (OTC PINKS: PHBI) ha anunciado un potencial de ingresos significativo a partir de su nuevo proyecto enfocado en la producción de Live Rosin, un concentrado de cannabis de alta calidad. El CEO Peter Wojcik detalló la técnica de extracción propia de la empresa y los Procedimientos de Cultivo Orgánico Estándar No-Rociados, que tienen como objetivo producir 6,000 litros de Live Rosin por cada finca de 100 acres por ciclo de cultivo. Con 4-5 ciclos de cultivo al año, Pharmagreen proyecta ingresos que oscilan entre 19 millones y 381 millones de dólares en el primer año, y entre 32 millones y 635 millones de dólares para el tercer año, dependiendo del precio por gramo. La empresa está buscando distribuidores y asociaciones, y explorando la adquisición de un laboratorio de cannabis certificado cGMP en Europa. Sin embargo, estas proyecciones dependen de obtener las licencias, permisos, arrendamientos de tierras, financiamiento y acceso al mercado necesarios.
Pharmagreen Biotech (OTC PINKS: PHBI)은 고품질 대마 농축물인 Live Rosin 생산에 중점을 둔 새로운 프로젝트에서 상당한 수익 잠재력을 발표했습니다. CEO 피터 Wojcik은 회사의 고유한 추출 기술과 표준 유기농 무분무 재배 절차에 대해 설명했으며, 이 절차는 100에이커 농장에서 각각의 재배 주기당 6,000리터의 Live Rosin을 생산하는 것을 목표로 하고 있습니다. 연간 4-5회 재배 주기를 통해 Pharmagreen은 1년차에 1,900만 달러에서 3억 8,100만 달러, 3년차에는 3,200만 달러에서 6억 3,500만 달러의 수익을 예상하고 있으며, 이는 그램당 가격에 따라 달라집니다. 회사는 유통업체 및 파트너십을 찾고 있으며, 유럽에 cGMP 인증 대마 실험실 인수 가능성을 탐색하고 있습니다. 그러나 이러한 예측은 필수적인 라이선스, 허가, 토지 임대, 자금 조달 및 시장 접근 확보에 따라 달라집니다.
Pharmagreen Biotech (OTC PINKS: PHBI) a annoncé un potentiel de revenus significatif grâce à son nouveau projet axé sur la production de Live Rosin, un concentré de cannabis de haute qualité. Le PDG Peter Wojcik a détaillé la technique d'extraction propriétaire de l'entreprise et les Procédures de Culture Organique Standards Non-Spray, qui visent à produire 6 000 litres de Live Rosin par ferme de 100 acres par cycle de culture. Avec 4 à 5 cycles de culture par an, Pharmagreen projette des revenus allant de 19 millions à 381 millions de dollars la première année, et de 32 millions à 635 millions de dollars d'ici la troisième année, selon le prix par gramme. L'entreprise recherche des distributeurs et des partenariats, tout en explorant l'acquisition d'un laboratoire de cannabis certifié cGMP en Europe. Cependant, ces projections dépendent de l'obtention des licences, des permis, des baux fonciers, du financement et de l'accès au marché nécessaires.
Pharmagreen Biotech (OTC PINKS: PHBI) hat ein erhebliches Umsatzpotenzial aus ihrem neuen Projekt angekündigt, das sich auf die Produktion von Live Rosin, einem hochwertigen Cannabis-Konzentrat, konzentriert. CEO Peter Wojcik erläuterte die firmeneigene Extraktionstechnik und die Standard-Organische-Nicht-Spray-Anbauverfahren, die darauf abzielen, 6.000 Liter Live Rosin pro 100 Morgen Farm und Erntezyklus zu produzieren. Mit 4-5 Erntezyklen pro Jahr prognostiziert Pharmagreen Einnahmen zwischen 19 Millionen und 381 Millionen Dollar im Jahr 1 sowie zwischen 32 Millionen und 635 Millionen Dollar bis Jahr 3, abhängig vom Preis pro Gramm. Das Unternehmen sucht nach Distributoren und Partnerschaften und prüft den Erwerb eines cGMP-zertifizierten Cannabis-Labors in Europa. Diese Prognosen hängen jedoch von der Sicherstellung der erforderlichen Lizenzen, Genehmigungen, Pachtverträge, Finanzierung und Marktzugang ab.
- Potential revenue of $19 million to $381 million in year 1.
- Revenue could grow to $32 million to $635 million by year 3.
- Live Rosin produced through a solventless extraction process ensuring high quality.
- Proprietary cultivation techniques enhancing crop quality.
- Revenue projections depend on securing licenses, permits, and funding.
- Outcomes cannot be guaranteed at this stage.
CARSON CITY, Nev., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) ("Pharmagreen" or the "Company") is thrilled to highlight the significant revenue potential from its latest project under development. During a special session on Creative Spaces, hosted on X on Monday, October 7, 2024, CEO Peter Wojcik shared exciting insights into the company's business advancements and growth strategies.
Pharmagreen is developing a specialized form of cannabis oil known as Live Rosin, a highly sought-after cannabis concentrate recognized for its unmatched purity, potency, and rich flavor profile. Produced through a solventless extraction process that uses no chemical solvents, Live Rosin sets a new standard for quality in the cannabis industry. Pharmagreen’s proprietary extraction technique ensures the highest cannabinoid recovery rates, while maintaining the plant’s natural properties. This process is further enhanced by the company’s exclusive Standard Organic Non-Spray Cultivation Procedures (SONSCP), ensuring the optimal cultivation and quality of their crops.
Pharmagreen’s innovative farming and processing model is designed to yield an average of 6,000 liters of Live Rosin per 100-acre farm, per crop cycle, depending on the cannabinoid content of the plants. With 4 to 5 crop cycles per year, depending on the strain, the company is poised for significant production output. Live Rosin currently commands retail prices ranging from
Pharmagreen’s projected revenues are impressive:
- At
$1 per gram, estimated gross revenues are$19 million in year 1, rising to$32 million by year 3. - At
$5 per gram, revenues are projected to reach$95 million in year 1 and$158 million by year 3. - At
$10 per gram, revenues could soar to$190 million in year 1, growing to$317 million by year 3. - At
$20 per gram, revenue estimates reach$381 million in year 1, and a staggering$635 million by year 3.
To ensure successful distribution and market access for its premium Live Rosin, Pharmagreen is actively seeking distributors, joint venture partnerships, and is exploring the acquisition of a cGMP-certified cannabis lab in Europe. This strategic move would enable Pharmagreen to tap into the lucrative EU cannabis market, where Live Rosin commands even higher prices.
While these revenue projections are grounded in extensive market research and current industry conditions, they are dependent on the successful completion of several key milestones. These include securing cannabis production and processing licenses, export/import permits from foreign governments, land leases, and the necessary funding to establish the cannabis farm and processing facility, as well as ensuring market access for product sales. Pharmagreen is making consistent progress toward these critical objectives, though outcomes cannot be guaranteed at this stage.
Peter Wojcik, CEO of Pharmagreen Biotech Inc., stated, "The revenue projections are indeed promising, and I am eager to bring them to fruition once the initial milestones are achieved. This is an exciting project, and it’s a privilege to be leading its development."
For more details on CEO Peter Wojcik's session on Creative Spaces, please visit
Pharmagreen’s X page at Pharmagreen on X.
About Pharmagreen Biotech, Inc.
Pharmagreen is actively advancing its current project while simultaneously developing its nutraceutical product line, with a strong emphasis on generating revenue from its proprietary MaxGenomic™ blend of therapeutic plants and mushrooms, as well as future wellness supplements. Leveraging its expertise in cultivation technologies and plant genetics, Pharmagreen is conducting research into advanced transgenic plant technologies to create nutraceuticals and daily supplements aimed at enhancing health and addressing a wide range of conditions.
For company’s online store, please visit:
https://www.amazon.com/MaxGenomicTM-Supplement-Broadspectrum-Wellness-Beneficial/dp/B0C9C656KR
Safe Harbor Statement
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.
The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.
Contact Information:
Tel: (702) 803 9404
Email: info@pharmagreen.ca
Online Store: www.maxgenomicproducts.com
Corporate Website: www.pharmagreen.ca
FAQ
What is Pharmagreen Biotech's latest project?
What are the revenue projections for Pharmagreen Biotech's Live Rosin project?
What are the key factors for Pharmagreen Biotech to achieve its revenue projections?
What makes Pharmagreen Biotech's Live Rosin unique?
What strategic moves is Pharmagreen Biotech considering for its Live Rosin project?
